Gilead struggles to shift debate over $1,000 hepatitis pills from costs to cures

When Gilead Sciences Inc. President John Milligan recently told Wall Street analysts that he expected more stories centering on the growing number of patients benefitting from the company’s pricey hepatitis C drug Sovaldi, he wasn’t kidding...